Stay updated with breaking news from Janssen Bayer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PRINCETON, N.J., July 07, 2023 -- CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its...
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its
AstraZeneca announced the ANNEXA phase IV trial assessing the safety and efficacy of andexanet alfa stopped early after achieving prespecified criteria on hemostatic efficacy vs. usual care, according to a press release. Andexanet alfa (Andexxa) is approved for patients prescribed oral factor Xa inhibitor treatment, including apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) and rivaroxaban
Among older patients with atrial fibrillation and dementia, apixaban was associated with lower risk for stroke and major bleeding vs. dabigatran, rivaroxaban or warfarin, researchers reported. The association was also detected in patients with AF but no dementia, but to a lesser degree.
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...